News

Home/News/

In Memory of Phil Ralston

phil-ralston-post

Phil Ralston passed away Saturday, July 4, 2015, after a 23 month battle with cancer. Phil led MacuCLEAR, Inc. for more than nine years. He took on the challenge of bringing Dr. George Chiou’s exciting discovery from the university laboratory to the marketplace because he was motivated to help people fight the terrible diagnosis of macular degeneration. His tenacious leadership and effortless dedication to the mission of MacuCLEAR has moved the technology from discovery to the clinic. While there is still much work to be done to fully realize the promise of […]

2017-05-23T18:33:42+00:00 September 15, 2015|Categories: In the News|0 Comments

Eye Drops Could Treat Age-Related Macular Degeneration

A drop a day might soon keep blindness away. Researchers say they have found a possible treatment for age-related macular degeneration (AMD) — the leading cause of blindness among the elderly — that could be delivered via eye drops.

There currently is no cure for AMD, nor is there a treatment for its most common form, the so-called dry AMD, which affects 90 percent of AMD suffers. The new research, which was conducted in animals, could lead to treatment for people with AMD in the future, the researchers said.

Read the Full Article

2017-05-23T18:33:42+00:00 October 15, 2013|Categories: In the News|0 Comments

Texas A&M System Technology Commercialization: MacuCLEAR


The Texas A&M System Technology Commercialization is Industry’s Connection to the A&M System. The TTC provides the link between the laboratories where innovative new technologies are being developed and industry partners that will bring them to fruition as a product.

The TTC protects these new innovations, developed by A&M System researchers, through patents and copyrights and seeks to transfer the intellectual property to industry by royalty-bearing license agreements for commercial products that result in economic development and public benefit.

The TTC interacts with hundreds of companies each year as it seeks to find commercial partners to commercialize […]

2017-05-23T18:33:42+00:00 July 8, 2013|Categories: In the News|0 Comments

Raises More Than $1M In Financing And Enters Into Strategic Pacific Rim Partnership – The Street

MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, today announced it has secured more than $1M in funds from current investors.  The funds will be used to complete a pivotal, Phase 3a human efficacy trial for its lead product, MC-1101.  Concurrently, MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in the territory.

Read the Full Article

2017-05-23T18:33:43+00:00 January 3, 2012|Categories: In the News|0 Comments

Raises More then $1M in Financing and Enters into Partnership – Digital Journal

MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, today announced it has secured more than $1M in funds from current investors.  The funds will be used to complete a pivotal, Phase 3a human efficacy trial for its lead product, MC-1101.  Concurrently, MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in the territory.

Read the Full Article
2017-05-23T18:33:43+00:00 January 3, 2012|Categories: In the News|0 Comments